Showing 2091-2100 of 2652 results for "".
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Elios Vision Announces Collaboration with the International Glaucoma Surgical Registryhttps://modernod.com/news/elios-vision-announces-collaboration-with-the-international-glaucoma-surgical-registry/2481708/Elios Vision has announced its collaboration and support for the International Glaucoma Surgical Registry (IGSR), an open access tool which enables surgeons to upload and analyze their data and compare outcomes with other centers. The IGSR was established more than 5 years ago and currently
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w
- Cellusion Raises $21 Million to Advance iPS Cell-Derived Corneal Endothelial Cell Substitutehttps://modernod.com/news/cellusion-raises-21-million-to-advance-ips-cell-derived-corneal-endothelial-cell-substitute/2481659/Tokyo-based Cellusion announced that it has raised 2.83 billion yen ($21 million USD) in Series C Round financing. The funding will be used to promote its lead program—the development of iPS cell-derived corneal endothelial cell substitute (CLS001) to resolve the challenge of
- SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conferencehttps://modernod.com/news/sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference/2481654/With a goal to improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference taking place from June 9-11 in Manchester, England. Three-Year Myopia Control Eff